331 related articles for article (PubMed ID: 23784266)
21. Application of Static Modeling --in the Prediction of In Vivo Drug-Drug Interactions between Rivaroxaban and Antiarrhythmic Agents Based on In Vitro Inhibition Studies.
Cheong EJ; Goh JJ; Hong Y; Venkatesan G; Liu Y; Chiu GN; Kojodjojo P; Chan EC
Drug Metab Dispos; 2017 Mar; 45(3):260-268. PubMed ID: 28053220
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48).
Ruff CT; Giugliano RP; Antman EM; Crugnale SE; Bocanegra T; Mercuri M; Hanyok J; Patel I; Shi M; Salazar D; McCabe CH; Braunwald E
Am Heart J; 2010 Oct; 160(4):635-41. PubMed ID: 20934556
[TBL] [Abstract][Full Text] [Related]
23. Interaction between topically and systemically coadministered P-glycoprotein substrates/inhibitors: effect on vitreal kinetics.
Hippalgaonkar K; Srirangam R; Avula B; Khan IA; Majumdar S
Drug Metab Dispos; 2010 Oct; 38(10):1790-7. PubMed ID: 20595378
[TBL] [Abstract][Full Text] [Related]
24. An integrated pharmacokinetic/pharmacogenomic analysis of ABCB1 and SLCO1B1 polymorphisms on edoxaban exposure.
Vandell AG; Lee J; Shi M; Rubets I; Brown KS; Walker JR
Pharmacogenomics J; 2018 Jan; 18(1):153-159. PubMed ID: 27897269
[TBL] [Abstract][Full Text] [Related]
25. Effects of food on the pharmacokinetics of edoxaban, an oral direct factor Xa inhibitor, in healthy volunteers.
Mendell J; Tachibana M; Shi M; Kunitada S
J Clin Pharmacol; 2011 May; 51(5):687-94. PubMed ID: 20534818
[TBL] [Abstract][Full Text] [Related]
26. Co-administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects.
Mueck W; Kubitza D; Becka M
Br J Clin Pharmacol; 2013 Sep; 76(3):455-66. PubMed ID: 23305158
[TBL] [Abstract][Full Text] [Related]
27. A prospective evaluation of edoxaban compared to warfarin in subjects undergoing cardioversion of atrial fibrillation: The EdoxabaN vs. warfarin in subjectS UndeRgoing cardiovErsion of Atrial Fibrillation (ENSURE-AF) study.
Lip GY; Merino J; Ezekowitz M; Ellenbogen K; Zamoryakhin D; Lanz H; Jin J; Al-Saadi N; Mercuri M; Goette A
Am Heart J; 2015 May; 169(5):597-604.e5. PubMed ID: 25965706
[TBL] [Abstract][Full Text] [Related]
28. Edoxaban: A Novel Factor Xa Inhibitor for the Management of Non-valvular Atrial Fibrillation and Venous Thromboembolism.
Kubli KA; Snead JA; Cheng-Lai A
Cardiol Rev; 2016; 24(4):205-10. PubMed ID: 26991962
[TBL] [Abstract][Full Text] [Related]
29. Pharmacokinetics of the oral direct renin inhibitor aliskiren in combination with digoxin, atorvastatin, and ketoconazole in healthy subjects: the role of P-glycoprotein in the disposition of aliskiren.
Vaidyanathan S; Camenisch G; Schuetz H; Reynolds C; Yeh CM; Bizot MN; Dieterich HA; Howard D; Dole WP
J Clin Pharmacol; 2008 Nov; 48(11):1323-38. PubMed ID: 18784280
[TBL] [Abstract][Full Text] [Related]
30. A randomized trial of the safety, pharmacokinetics and pharmacodynamics of edoxaban, an oral factor Xa inhibitor, following a switch from warfarin.
Mendell J; Noveck RJ; Shi M
Br J Clin Pharmacol; 2013 Apr; 75(4):966-78. PubMed ID: 22924409
[TBL] [Abstract][Full Text] [Related]
31. Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation.
Weitz JI; Connolly SJ; Patel I; Salazar D; Rohatagi S; Mendell J; Kastrissios H; Jin J; Kunitada S
Thromb Haemost; 2010 Sep; 104(3):633-41. PubMed ID: 20694273
[TBL] [Abstract][Full Text] [Related]
32. Drug interaction between oral atorvastatin and verapamil in healthy subjects: effects of atorvastatin on the pharmacokinetics of verapamil and norverapamil.
Choi DH; Shin WG; Choi JS
Eur J Clin Pharmacol; 2008 May; 64(5):445-9. PubMed ID: 18193210
[TBL] [Abstract][Full Text] [Related]
33. Effects of HM30181, a P-glycoprotein inhibitor, on the pharmacokinetics and pharmacodynamics of loperamide in healthy volunteers.
Kim TE; Lee H; Lim KS; Lee S; Yoon SH; Park KM; Han H; Shin SG; Jang IJ; Yu KS; Cho JY
Br J Clin Pharmacol; 2014 Sep; 78(3):556-64. PubMed ID: 24602137
[TBL] [Abstract][Full Text] [Related]
34. Effect of saquinavir/ritonavir on P-glycoprotein activity in healthy volunteers using digoxin as a probe.
Schmitt C; Kaeser B; Riek M; Bech N; Kreuzer C
Int J Clin Pharmacol Ther; 2010 Mar; 48(3):192-9. PubMed ID: 20197013
[TBL] [Abstract][Full Text] [Related]
35. Safety and efficacy of dronedarone from clinical trials to real-world evidence: implications for its use in atrial fibrillation.
Boriani G; Blomström-Lundqvist C; Hohnloser SH; Bergfeldt L; Botto GL; Capucci A; Lozano IF; Goette A; Israel CW; Merino JL; Camm AJ
Europace; 2019 Dec; 21(12):1764-1775. PubMed ID: 31324921
[TBL] [Abstract][Full Text] [Related]
36. Role of P-glycoprotein in the intestinal absorption of tanshinone IIA, a major active ingredient in the root of Salvia miltiorrhiza Bunge.
Yu XY; Lin SG; Zhou ZW; Chen X; Liang J; Liu PQ; Duan W; Chowbay B; Wen JY; Li CG; Zhou SF
Curr Drug Metab; 2007 May; 8(4):325-40. PubMed ID: 17504222
[TBL] [Abstract][Full Text] [Related]
37. Edoxaban vs warfarin in patients with nonvalvular atrial fibrillation in the US Food and Drug Administration approval population: An analysis from the Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48 (ENGAGE AF-TIMI 48) trial.
Eisen A; Giugliano RP; Ruff CT; Nordio F; Gogia HS; Awasty VR; Henderson DA; Mercuri MF; Rutman H; Antman EM; Braunwald E
Am Heart J; 2016 Feb; 172():144-51. PubMed ID: 26856226
[TBL] [Abstract][Full Text] [Related]
38. Vitreal kinetics of quinidine in rabbits in the presence of topically coadministered P-glycoprotein substrates/modulators.
Majumdar S; Hippalgaonkar K; Srirangam R
Drug Metab Dispos; 2009 Aug; 37(8):1718-25. PubMed ID: 19406953
[TBL] [Abstract][Full Text] [Related]
39. Comparison of a direct Factor Xa inhibitor, edoxaban, with dalteparin and ximelagatran: a randomised controlled trial in healthy elderly adults.
Samama MM; Kunitada S; Oursin A; Depasse F; Heptinstall S
Thromb Res; 2010 Oct; 126(4):e286-93. PubMed ID: 20807664
[TBL] [Abstract][Full Text] [Related]
40. Clinical relevance of pharmacokinetic and pharmacodynamic properties of edoxaban when treating patients with atrial fibrillation and heart failure.
Aspromonte N; Colivicchi F
Expert Opin Drug Metab Toxicol; 2017 Jan; 13(1):113-122. PubMed ID: 27819149
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]